Aclaris Therapeutics Inc
ACRS
Get informed when a big investor buys or sells
+ FollowMarket Cap$548.71M
Close$
$-0.99
122.5% downside
Current Fair Value
122.5% downsideOvervalued by 122.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $548.71 Million |
|---|---|
| Enterprise Value | $526.00 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.53 |
| Beta | 0.78 |
| Outstanding Shares | 128,810,050 |
Return
| Return on Equity | -48.49% |
|---|---|
| Return on Assets | -35.06% |
| Return on Invested Capital | -43.52% |
Valuation & Multiples
| P/E Ratio | -8.41 |
|---|---|
| PEG | -26.78 |
| Price to Sales | - |
| Price to Book Ratio | 4.42 |
| Enterprise Value to Revenue | 62.87 |
| Enterprise Value to EBIT | -7.05 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-0.16
Average shareholder expectationRevenue Estimate
$1.24 M
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-0.16
Average shareholder expectationRevenue Estimate
$1.38 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.3682▲ 36.82% |
|---|---|
| Total Calls | 644,200▼ 44.02% |
| Total Puts | 237,200▲ Infinity% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 88.63%▲ 20.34% |
|---|---|
| Total Invested | $407.55M▲ 61.69% |
| Investors Holding | 140▲ 16.00% |
ESG Score
No data
About Aclaris Therapeutics Inc
CEO: Neal Walker